References
- American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009;32(Suppl. 1):S13-61
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
- The International Diabetes Federation (IDF). Global Guideline for Type 2 Diabetes. Available at: http://www.idf.org/home/index.cfm?node=1457 (Last accessed 30 October 2010)
- Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag 2008;4:561-74
- Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
- Bainbridge KE, Cowie CC, Rust KF, et al. Mitigating case mix factors by choice of glycaemic control performance measure threshold. Diabetes Care 2008;31:1754-60
- Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008;51:1790-5
- Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
- Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
- Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700
- German Diabetes Association. Guidelines for diabetes care. Available at: http://www.diabetes.versorgungsleitlinien.de/ (Last accessed 30 October 2010)
- Henderson JN, Allen KV, Deary LJ, et al. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-21
- Gao Y, Guo XH, Vaz JA; the PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diab Obes Metab 2009;11:33–40
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
- Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- Liebl A, Prager R, Binz K, et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diab Obes Metab 2009;11:45-52
- The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008;358:2545-59
- Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-90
- Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005;27(Suppl. B):S42-56
- Peter R, Okoseime OE, Rees A, et al. Postprandial glucose – a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009;7:68-74
- Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9
- Jenkins N, Hallowell N, Farmer AJ, et al. Initiating insulin as part of the treating to target in type 2 diabetes (4-T) trial: an interview study of patients’ and health professionals’ experiences. Diabetes Care 2010;33:2178-80